There is a particular exhaustion that belongs to people who have tried to treat their depression and found that the treatments did not work. The effort of evaluations, adjustments, side effects weathered in hope of relief that did not come. The slow accumulation of evidence that the standard paths are not going to be the path.
Treatment-resistant depression is not a character state. It is a clinical presentation with a specific definition, well-studied mechanisms, and interventions that were developed precisely because the standard first- and second-line treatments are not adequate for everyone. If you are in this, knowing what it actually means is a useful starting point.
What the Diagnosis Actually Means
Treatment-resistant depression (TRD) is generally defined as depression that has not responded adequately to at least two antidepressant trials of appropriate dose and duration. This definition is not a judgment about effort or attitude. It reflects a clinical reality: the biological mechanisms underlying depression are heterogeneous, and the interventions that work for one presentation do not work for all of them.
Roughly a third of people diagnosed with major depressive disorder will meet criteria for TRD at some point. It is not rare, and its persistence is not evidence of inadequate treatment effort on the patient's part. It is evidence that the treatment match has not yet been found.
Why Standard Treatments Sometimes Fail
Conventional antidepressants primarily work on serotonin, norepinephrine, or dopamine reuptake. For many people, these mechanisms produce meaningful relief. For others, the underlying neurobiology of their depression involves different systems, and these medications offer incomplete coverage.
Factors that contribute to treatment resistance include the presence of unaddressed co-occurring conditions (anxiety, ADHD, trauma history, sleep disorders), incorrect diagnosis, inadequate trial duration, and in some cases, genetic variations that affect how medications are metabolized. A thorough evaluation can identify some of these factors and inform a different treatment approach.
What Anhedonia Is and Why It Matters
One of the most debilitating features of treatment-resistant depression is anhedonia: the loss of the capacity to feel pleasure. Not merely reduced enjoyment, but a flat, affectless absence of response to things that once produced interest, joy, or desire.
Anhedonia is not a mood. It is a neurological state. The reward circuitry that generates motivation, anticipation, and the felt experience of positive emotion has gone quiet. People with significant anhedonia often describe going through the motions of their life without being able to feel any of it, present in form, absent in experience.
This matters for treatment selection because some interventions specifically target the neurobiological systems that underlie anhedonia in ways that conventional antidepressants do not. Understanding anhedonia as a discrete symptom, not simply a feature of low mood, points toward different treatment levers.
What Options Exist Beyond Standard Antidepressants
At Inner Journey Healthcare, two interventions specifically designed for treatment-resistant depression are available:
Ketamine-Assisted Psychotherapy (KAP) uses ketamine in a supervised, structured therapeutic context. Ketamine operates on the glutamate system and appears to produce rapid increases in neuroplasticity, the brain's capacity to form new connections. Clinical trials have demonstrated rapid reductions in depressive symptoms, including anhedonia, in people who have not responded to multiple prior treatments. The neuroplasticity window ketamine opens is used therapeutically: the preparation and integration work surrounding each dosing session is designed to help that window become lasting change, not a temporary state.
Spravato (esketamine) is the FDA-approved nasal spray version of ketamine, specifically approved for treatment-resistant depression. Spravato is administered in our office with medical monitoring, and is covered in-network by several Montana insurance plans including BCBS MT, PacificSource, and Aetna. Making it one of the most accessible options in the state for patients who have not responded to standard antidepressants.
On restoring what depression takes:
Treatment-resistant depression, and particularly the anhedonia it produces, represents one of the most complete thefts of lived experience. The absence of pleasure is not simply sadness. It is the absence of color in ordinary life. The interventions available for TRD — KAP, Spravato, and optimized pharmacotherapy — are not palliative adjustments. They are specifically targeted at restoring the capacity for experience that depression has removed. That restoration is the clinical goal. Feeling better is not a side effect. It is the point.
What to Expect at Inner Journey
Every patient who comes to Inner Journey for TRD evaluation begins with a comprehensive psychiatric intake. I review their full treatment history, current medications, co-occurring conditions, and goals. From that evaluation, I develop a recommendation that is specific to their situation — not a default protocol, but a considered plan.
For patients who proceed with KAP or Spravato, the full therapeutic model is in place: preparation before dosing, physician and therapist presence throughout, and integration therapy after. The clinical outcome we are working toward is not just symptom reduction. It is a meaningful change in how you experience your life.
If you have been in the position of trying treatments that have not worked, we are glad to talk through what might be different. A conversation is a reasonable place to start.
Education only, not medical advice. Talk with a qualified provider before starting light therapy or any new treatment.

